 This is an open-label, multi-centre, randomised Phase III study, looking at a series of 480 patients up to the age of 65 with newly diagnosed multiple myeloma MM not previously treated. They will receive VAD or Velcadedexamethasone combination as induction treatment plusminus dexamethasonecyclophosphamideetoposidecisplatin DCEP followed by autograft as first-line therapy, as the investigators try to compare the complete remission CR rate with negative or positive immunofixation at the end of their induction treatment. 